Patient inclusion for the CKD-bioMatch trial has started in the University Medical Center Hamburg Eppendorf.

This new clinical trial, an important part of the PRIME-CKD project, has been initiated, aiming to improve treatment for patients with progressive chronic kidney disease (CKD).This initiative represents a major step toward bringing precision medicine from the lab to the clinic, using real biological signals to guide treatment decisions.

The CKD-bioMatch trial is recruiting 125 patients with progressive CKD. Patients from Denmark, Germany, Spain, United Kingdom and Sweden are being included for the trial that will run for 3 years

Prof. Dr. Tobias B. Huber, MD, Director of the  III. Department of Medicine and Hamburg Center for Kidney Health, University Medical Center Hamburg Eppendorf says:

“We are excited to advance this project and the personalization of medical therapies, thereby progressively improving the quality of care for patients living with kidney disease.”

Dr. Elisabeth Meister, MD and clinician scientist, working in the team of Prof. Huber at the University Medical Center Hamburg Eppendorf adds:

“The preparation and planning of this international multicenter study represents an outstanding achievement that was only made possible through the close collaboration of all partners involved, enabling us to provide our patients with access to the most advanced therapeutic approaches.”

Coordinator of PRIME-CKD Hiddo L. Heerspink (UMCG, The Netherlands) comments on the start  of  the CKD-bioMatch trial:

“The enrolment of the first patients into the CKD-bioMatch trial marks an important step towards a better understanding how to personalize the treatment of CKD” says Hiddo L. Heerspink, PRIME-CKD coordinator. “This study pioneers a personalized medicine approach by using biological markers (biomarkers) to guide treatment, ensuring that the right drug reaches the right patient at the right time.”

What this may mean in practice
If successful, CKD-bioMatch could help patients receive effective therapy sooner. By identifying non-responders early, clinicians may prevent avoidable disease progression and reduce the likelihood of severe complications such as dialysis.

For healthcare systems, biomarker-guided therapy has the potential to improve treatment efficiency by focusing resources on therapies that offer measurable benefit. This could support future decision-making for reimbursement, guideline development and long-term kidney-health strategies.

PRIME-CKD – 12/1/2026